

Givetime.io

Changing the paradigm of human life



Content

- About the project
- Goals
- The relevance of science and information technology in medicine
- Investments in medical startups
- Project principles
- Tokenomics
- Implementation of the offline part of the project
- Road map
- Benefits of project investor
- Team
- Connections

About the project

Givetime.io project - founded November 1, 2021. Place of residence of the founder, Ukraine, Kharkiv. To get to know it better, we recommend that you study the first interview about the project. It is available at the link.

At the moment, the team has +6 people who are actively involved in the development of the project plan and take part in its implementation. We are also actively developing communication with important participants in both the crypto world and the science and medicine market.

We publish all important events, announcements and events on our social networks.

<https://www.facebook.com/givetimeio/>

<https://twitter.com/givetimeio>

<https://t.me/givetimechat>

<https://medium.com/@givetimeio>

<https://www.linkedin.com/company/80770579/>

At the moment, we already have more than 250 investors who believe in the project and wish to take an important part through it in the entire industry of medicine and the development of science, which will be useful for the human body and influence its quality of life.

Goals

Our main goal is to change a person's thinking and life planning

We want to positively influence the revolution in medicine and the use of technology to diagnose and treat the body. Here are a number of problems that we consider the main ones, and we offer a number of solutions to them.

Problems

1. The slow growth of medical capacity, the insignificant effect of progress in medicine on human health, and quality of life.
2. Weak integration of science in the diagnosis of the human condition and treatment of diseases - both congenital and acquired.
3. Scientific advances in medicine are rarely implemented. They often remain “on paper”, blocked by patent restrictions and bureaucracy. If the restrictions and all legal issues are settled, a long-term period of integration of scientific knowledge and achievements in real life is required. They will be implemented in developed countries first, with limited access. Decades may pass before the technology is widely accepted.
4. Perception of the current situation as a given, without the possibility to change it. The current situation is considered “normal”.
5. Scientists are supported on a leftover basis. The most important role is frequently played by charities and individuals. The government stands aside from this issue, especially in developing countries. Developments are ignored and lost.

Solution

1. The launch of a marketing campaign focused on increasing the value of health, quality and opportunities of medicine
2. Creation of a non-profit organization. It will include research centers, R&D centers, clinics for the practical implementation of knowledge and technologies.
3. Formation of the main directions of development that require a revolution in the methods of diagnosis and treatment. Special attention should be paid to rare diseases that are currently considered as “commercially impractical” to research.
4. Creation of a development ecosystem that will bring together researchers, scientists, medicine, and IT specialists. Creation of a global cluster that will work on solving issues.

Goals for the next 10 years:

1. Increasing the human life expectancy by 10 years until 2032. Development in this direction, search for current constraints and their elimination.
2. Increasing the medical capacity and abilities of medical professionals in the diagnosis and treatment of diseases.
3. Increasing the ability to diagnose health conditions for everyone.
4. Creation of a research center and clinic within the framework of a solution to main problems.

Directions of the project:

The first part of directions for the project

1. Development of modern equipment - both for professional and home usage.
Expanding the possibilities of diagnosing the state of blood vessels and blood flows.
Emphasis on this area as the main method for studying strokes and heart attacks.

The second part of the project directions

2. Development of a mobile/stationary blood oxygen enrichment apparatus. A modern and quick solution, an alternative to mechanical ventilation and ECMO (the problem of maintaining a person's life with severe lung damage).
3. Study of the detailed effect of viruses on the human body. Development of methods that will influence the course of the disease (as currently, medicine is powerless in the fight against viruses).
4. Development of methods for the diagnosis of cancerous tumors in the early stages.
In-depth study of blood and other indicators of the body, which will make it possible to accurately determine and describe the processes. The possibility of treating diseases in the early stages.
5. The launch of a program for the development of treatment for children with severe illnesses under 10 y.o.
6. Fighting dementia and Alzheimer's. Development of methods of early diagnosis, designing a program of prevention and treatment of this disease.


Detailing the two directions of the project

In order to assess and show the importance of these areas comprehensively, we propose to study such data as:

1. The scale of the problem in the world
2. Existing solutions and their success
3. Alternative Solutions
4. Projects that deal with these issues
5. Market assessment for these services and destinations
6. The opinion of well-known experts regarding the importance of solving these problems

Causes of death in the world in 2019 (before the coronavirus epidemic)

Leading causes of death globally




Source: WHO Global Health Estimates.

Source: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>

If we're talking about estimating causes of death in upper-middle-income countries.

Leading causes of death in upper-middle-income countries




Source: WHO Global Health Estimates. Note: World Bank 2020 income classification.

Source: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>

If we're talking about estimating causes of death in high-income countries.

Leading causes of death in high-income countries



Source: WHO Global Health Estimates. Note: World Bank 2020 income classification.

Source: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>

Conclusions: Strokes, heart attacks, lung disease are the most common mortality problems. People most often face such problems that can end a person's life. A large number of deaths indicates the lack of successful methods of treatment, diagnosis and prevention of these problems. Current medicine and doctors are less successful in counteracting these diseases, which leads to the death of the bulk of people.

A study of the sectors of upper-middle and high-income countries was conducted to assess the ability of countries and individuals to pay for the diagnosis and treatment of current problems at a priority level. And also to take an active part in the development of new drugs and equipment for the treatment of these ailments.

This can be considered an important factor in allocating money in the market and comparing the relevance of these problems and the allocation of funds to solve them.

Here is a summary of the main factors from the WHO portal:

- Cardiovascular diseases (CVDs) are the leading cause of death globally.
- An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.
- Over three quarters of CVD deaths take place in low- and middle-income countries.
- Out of the 17 million premature deaths (under the age of 70) due to noncommunicable diseases in 2019, 38% were caused by CVDs.
- Most cardiovascular diseases can be prevented by addressing behavioural risk factors such as tobacco use, unhealthy diet and obesity, physical inactivity and harmful use of alcohol.
- It is important to detect cardiovascular disease as early as possible so that management with counselling and medicines can begin.

Source: [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))

Confirmation of the high relevance of the direction is confirmed by the development of other projects aimed at solving these problems.

If you take the US healthcare market, given that these are the most pressing problems for people and for doctors as well. That can roughly estimate the amount of funds that people are ready to allocate to solve their problems and the problems of their loved ones.

The health care system in the United States of America occupies a leading position in the world in terms of the scale of resources concentrated in it. In terms of spending on healthcare, the United States ranks first in the world - both in absolute terms (\$2.26 trillion, or \$7,439 per person) and as a percentage of GDP (16%). The number of people employed in the industry is over 10 million people.

Source: https://en.wikipedia.org/wiki/Health_care_in_the_United_States

According to the WHO, the most common cause of death is coronary heart disease, accounting for 16% of total deaths worldwide.

The greatest increase in mortality since 2000 was due to this disease: by 2019, mortality from it increased by more than 2 million cases and reached 8.9 million cases. Stroke and chronic obstructive pulmonary disease are the second and third leading causes of death, accounting for approximately 11% and 6% of total deaths, respectively.

Lower respiratory tract infections remain the fourth leading cause of death in the world, and the first among infectious diseases.

In the US, this market can be estimated at about \$745 billion a year. (33% of all expenses). This is a combination of three problems.

We do not focus on just one country, but the US budget is shown as a reference and serves to potential investors to appreciate the importance of the direction and the project as a whole.

To analyze the markets of other countries

United Kingdom - \$65.142 billion (total budget \$197.4 billion)

Germany - \$149.5 billion (total budget \$453.056 billion)

France - \$103.29 billion (total budget \$313 billion)

Russia - \$29.27 billion (total budget \$88.7 billion)

Ukraine - \$3.36 billion (total budget \$10.2 billion)

The relevance of science and IT in medicine

We point to a number of publications that predict that the integration between the three strands will soon be deeper. Since over the solution of serious issues that have not yet been resolved, complex measures are needed in the search and development of solutions.

Quotes:

The technologies that will have the biggest impact are those that allow the patient to become the point of care - Dr Bertalan Meskó

Quote:

Perhaps in 10 years' time we will stop using the word patient - Lucile Blaise

Source: <https://www.bbc.com/storyworks/connecting-the-dots/how-will-the-future-treat-you>

Quote:

"What the research team has been able to do is boost heart muscle cell numbers by as much as 45% after a heart attack. That's a huge improvement!"

Source: <https://www.victorchang.edu.au/news/heart-attack-breakthrough>

Quote:

Heart disease is already the costliest illness to treat, topping trauma, mental disorders and cancer. By 2035, spending on cardiovascular care is projected to rise from \$175 billion now to \$450 billion.

Source:

<https://www.usnews.com/news/health-news/articles/2020-03-02/are-those-breakthrough-heart-studies-really-to-be-trusted>

Investments in medical startups

Below is a ranking of US venture funds and the largest transactions in which they participated:

1. Alexandria Venture Investments

Number of deals: 38 Major deals: Compass Therapeutics (\$132 million Series A); Moderna Therapeutics (\$500M Series G) Headquarters: California

2. New Enterprise Associates

Number of deals: 28. Major investments: Bright Health (\$200 million Series C); Galera Therapeutics (\$150M Series C) HQ: Maryland

3. Keiretsu Forum

Number of transactions: 27. Major investments: Attune Medical (\$16 million Series C); Jana Care (\$10M Series A) Headquarters: California

4. OrbiMed

Number of transactions: 24. Major investments: Alector (\$133 million series E); Constellation Pharmaceuticals (\$100M Series F) Headquarters: New York

5. ARCH Venture Partners

Number of transactions: 22. Major investments: Gossamer Bio (\$230 million series B); Rubius Therapeutics (\$100M Series C) Headquarters: Illinois

6. SV Health Investors

Number of transactions: 21. Major investments: Sutro Biopharma (\$85M series E); Avrobio (\$60M Series B) Headquarters: Massachusetts

7. Connecticut Innovations

Number of transactions: 20. Major investments: Arvinas (\$56 million series C); Rallybio (\$37M Series A) HQ: Connecticut

8. Keiretsu Capital

Number of transactions: 20. Major investments: Joylux (\$7 million series A); Toma Bioscience (\$6M Series C) Headquarters: Washington DC

9. 5AM Ventures

Number of transactions: 19. Major investments: IDEAYA Biosciences (\$94 million series B); Impel Neuropharma (\$68M Series D) Headquarters: California

10. Plug And Play Tech Center

Number of transactions: 19. Major investments: Owkin (\$16M Series A), Prellis Biologics (\$1.8M Series A1) Headquarters: California

Source: <https://pitchbook.com/>

Project values

Changing the paradigm of human life

Great-grandparents are usually the last living generation in many families. As the next generation is born, they're about 80-90 years young, which is more than the average life expectancy in most countries.

A person can lead an active, high-quality lifestyle up to 60-70 years of age. Our task is to increase this duration to 90-100 years.

People will be able to plan their "second youth" when they're 60, which gives them additional 20-25 years of life after retirement.

It is important to pay special attention to cognitive capabilities, as health should allow people to manage both work and hobbies.

Great-grandparents will take an active part in raising children. They will have an active lifestyle with no slowdown in body functions, no attention or memory loss. They will have a desire to live and understand life's purpose, thus easily solving age crises.

The quality of life

The quality of life is just as significant as its duration. The opportunities for children born with serious illnesses and dysfunctions are limited, and therefore they often lead a miserable life (no matter how long it may be).

There is no point in prolonging life if medicine and science are not able to improve their quality. This is a complex issue that can be solved by the joint efforts of doctors and scientists.

Life is priceless

Life can be evaluated in monetary terms, neither in fiat nor in a crypto asset. We can only assess the possibilities of improving human health through the interaction of science and medicine.

The knowledge and products are recorded in the GTM token

This includes patents, surgeries, drugs, equipment. This is all tied to the value of the project's token. When selling developments, a crypto asset can be converted into fiat or another crypto asset.

Following the whitepaper

Life and its quality are the highest value for everybody. The economic success of the project determines its effectiveness in product research and development.

Researchers, doctors, managers, lawyers, and governments are the driving force of the project.

Patenting “everything and everywhere”

Patenting is used to protect copyright and control the use of our methods. We do not limit the use of our technologies. We need to evaluate the performance and monitor the use of technology to move in the right direction.

International importance

The team plans to create a knowledge base with all the research open to the public and distributed through the Big Data hub after obtaining licenses and patents in all the countries.

Tokenomics

We issued a fixed number of token according to the approximate number of human population.

Quantity : 8,000,000,000 tokens.















Additional emission: No

Transaction fee - 0.1% towards the creator's wallet account

Burning - 0%

Blocking of tokens for a stable situation for diseases and courses.

<https://www.team.finance/view-coin/0x9dcD80748b6bDC6aF0B7d51253743f6Fdb226c34?name=Givetime&symbol=GTM>

	<p>Locked Givetime Tokens- 999,000,000.00 GTM</p> <p> LOCKED Locked 12/13/2021 • Unlocks 03/01/2030</p> <p>Owner: 0x8543DF4407f20Be51656c4477776Ac9a32E31C17</p>	<p>UNLOCK COUNTDOWN</p> <p>2944D – 0H – 0M – 37S</p>
	<p>Locked Givetime Tokens- 2,997,000,000.00 GTM</p> <p> LOCKED Locked 12/13/2021 • Unlocks 01/01/2027</p> <p>Owner: 0x8543DF4407f20Be51656c4477776Ac9a32E31C17</p>	<p>UNLOCK COUNTDOWN</p> <p>1788D – 23H – 58M – 59S</p>
	<p>Locked Givetime Tokens- 1,498,500,000.00 GTM</p> <p> LOCKED Locked 12/13/2021 • Unlocks 01/01/2026</p> <p>Owner: 0x8543DF4407f20Be51656c4477776Ac9a32E31C17</p>	<p>UNLOCK COUNTDOWN</p> <p>1423D – 23H – 56M – 10S</p>
	<p>Locked Givetime Tokens- 999,000,000.00 GTM</p> <p> LOCKED Locked 12/13/2021 • Unlocks 01/01/2025</p> <p>Owner: 0x8543DF4407f20Be51656c4477776Ac9a32E31C17</p>	<p>UNLOCK COUNTDOWN</p> <p>1058D – 23H – 52M – 36S</p>
	<p>Locked Givetime Tokens- 849,150,000.00 GTM</p> <p> LOCKED Locked 12/13/2021 • Unlocks 01/01/2024</p> <p>Owner: 0x8543DF4407f20Be51656c4477776Ac9a32E31C17</p>	<p>UNLOCK COUNTDOWN</p> <p>692D – 23H – 51M – 0S</p>
	<p>Locked Givetime Tokens- 499,500,000.00 GTM</p> <p> LOCKED Locked 12/13/2021 • Unlocks 01/01/2023</p> <p>Owner: 0x8543DF4407f20Be51656c4477776Ac9a32E31C17</p>	<p>UNLOCK COUNTDOWN</p> <p>327D – 23H – 47M – 45S</p>
	<p>Locked Givetime Tokens- 99,900,000.00 GTM</p> <p> LOCKED Locked 12/13/2021 • Unlocks 06/11/2022</p> <p>Owner: 0x8543DF4407f20Be51656c4477776Ac9a32E31C17</p>	<p>UNLOCK COUNTDOWN</p> <p>123D – 22H – 42M – 42S</p>

Description of blocking targets:

To implement the project, a large amount of funds is required. Therefore, in order for the funds for implementation to be directed to the development of the project, we created a system for blocking and unlocking tokens in a time interval, so as to release tokens into the market without knocking down the critical course, but at the same time saturate the project with funds for its successful implementation.

What blocking a token may indicate:

1. At the moment, the tokens are locked and will not be released to the market. The price will not collapse.
2. The unlock schedule is visible to all participants and the goals of the unlocks are clear to the community.
3. In the event of a low token rate, tokens can be re-locked until the project's tokenomics goal is reached. This will be highlighted on our social channels.

Distribution model:

Marketing - 13%

Development - 2%

Implementation of offline project initiatives- 75%

Stabilization fund - 10%

There is a default fund distribution model. The initial funds will be used for marketing and expanding the project team.

Note: *It is possible to switch to your own blockchain if such a need is identified and supported by the project development team.*

RoadMap

Stage 1 (01.06.22)

- Site restructuring
- Preparing a private sales company (conditions)
- Social networking life activation
- PR and marketing private sales
- Community Growth Strategies
- Project marketing

Stage 2 (01.11.22)

- Project marketing
- Formation of the project team
- Implementation of the Private Sales stage
- Ensuring legal security
- Creation of a non-profit project organization
- Formation of the scientific council
- Building partnerships
- Creation of an active community 50k
- Creation of an active program for project participants
- Creation of a scientific hub
- Important confirmation of the reality of the tasks set

Stage 3 (01.03.23)

- Project marketing
- Patents, technology rights, product protection
- The first presentation of the company, the start of development
- Access to crypto exchanges
- Development of a product for diagnosing the cardiovascular system
- Creating a personal account for participants

Stage 4 (01.10.23)

- Product marketing
- Project marketing
- Presentation of products and company
- Start of product sales
- Opening of representative offices
- Launch of a number of diagnostic centers

Stage 5 (01.06.24)

- Project marketing
- Creation of research centers
- Creation of project clinics
- Launch of new project work vectors
- Creation of a complete ecosystem of customer monitoring
- Start of partnership programs with states

Offline implementation

Due to its uniqueness, the project initially needed to create a sufficient amount of tokens, which will be sold in the future in order to launch and develop the project. Since the roadmap is based on offline development, hiring a large number of people, design departments and equipment creation, the costs of this will be impressive.

Many investors are now worried about when the tokens will be unlocked. This information is public and you can see it again in the tokenomics section. We have tried to describe in as much detail as possible the scheme for creating, distributing and locking tokens. When will they be unlocked and under what conditions will they hit the market. This is an important point that every project investor should take into account.

The result of the successful development of the project will be the launch of research centers and clinics. The organization will be non-profit, all profits from activities will be invested in research, development of equipment and methods of treatment.

The legal registration of the organization is planned at the 2nd stage of the project development. The main evaluation tool for the organization's products, the sale of rights to use patents and methods of treatment will be the GTM (Givetime) token. This will maintain its liquidity.

The implementation of the offline part of the project will increase the demand for the coin as the main way to use the services and goods of the project.

This section will be updated with each important step in the implementation of the offline part of the project. Also follow the developments on our official channels.

Benefits of being a project investor

Benefits for medium term investment (12 months):


- Open project and team. Ready to answer any question in the community. Publicly and privately.
- Token passed security audit - link
- Project founder passed KYS - link
- There is no large commission for token transactions. Only 0.1% is a good solution for arbitrage and trading.
- Tokens are locked. A clear system and conditions for their unlocking.
- The project is young. Hence has a minimum token valuation. Successful entry start, at the best prices.
- A real roadmap - into a physical product. Most of the other projects are focused only on online development.
- Investor packages are also available. At good token purchase prices.
- There is a clear exit program for CEX, at the beginning of tier 2-3, then tier 1.
- The development of the project product gives a clear understanding of how the GTM token will grow, what its purpose is, what driving forces it will have.
- The wide niche of the project's activities allows you to immediately assess the potential for community growth and the interest of all mankind in solving these goals.
- A huge market in the world and rich countries, both in terms of services and equipment. All this will be successfully used for popularization and rapid development of the project.

Benefits for long term investment (12-60 months):

- For the top 100. Closed community with the project team
- For the top 100. Priority clinic services
- For the top 100. Priority sale of diagnostic equipment
- For the top 100. Priority opportunity to use technologies, methods and patents
- For the top 1000. Priority clinic services
- For the top 1000. Invitation to conferences and presentations of the project
- For the top 1000. Priority sale of diagnostic equipment

Team

Our Team



Alexander Movchan

Founder | Ideologist



Andrew Khudokormov

Tokenomic | Manager




Denis Cherkashin

Relationship | Manager



Dmitriy Silenko

Journalist | Givetime.io



Mikhail Eremeychuk

Designer | Embodiment



Roberto Gerasimenko

Manager | Community



More - <https://givetime.io/team>

Connections

Website - <http://givetime.io/>

Telegram Channel - <https://t.me/givetimeio>

Telegram Channel (UA) - <https://t.me/givetimeioru>

Telegram Chat - <https://t.me/givetimechat>

Telegram Chat (UA) - <https://t.me/givetimeruchat>

Twitter - <https://twitter.com/givetimeio>

Medium - <https://medium.com/@givetimeio>

Useful resources

- 1) <https://givetime.io/>
- 2) <https://coinmarketcap.com//currencies/givetime-io/>
- 3) <https://finance.yahoo.com/news/givetime-io-presale-coin-december-120000209.html>
- 4) <https://www.bloomberg.com/press-releases/2021-11-23/givetime-io-new-presale-coin-in-december-2021>
- 5) <https://www.newsfilecorp.com/release/104819/Givetime.io-New-Presale-Coin-in-December-2021>
- 6) <https://medium.com/@givetimeio/three-important-questions-about-the-project-givetime-io-45748695929c>
- 7) <https://techstory.in/givetime-io-cryptocurrency-science-and-healthcare-interview-with-alexander-movchan/>